<article id="wealth_of_evidence" class="slide" data-ag-slide-name="Wealth of evidence">
    <div class="basic">
      <h1 id="wealth_of_evidence_pre_header" data-ag-editable="Wealth of evidence Pre Main Title">Clinical data overview</h1>
      <!--<h1 class="wealth_of_evidence_hidden_content" data-ag-editable="Wealth of evidence Post Main Title">A comparison of clinical relevance and evidence<sup>1–9</sup></h1>-->
      <div id="wealth_of_evidence_top_item_holder">
         <!-- Top Item-->
         <div id="wealth_of_evidence_list_top_item_holder" class="wealth_of_evidence_list_item_holder">
            <div id="wealth_of_evidence_list_top_tick1" class="wealth_of_evidence_list_tick_left_empty"></div>
            <div id="wealth_of_evidence_list_top_item" class="wealth_of_evidence_list_items">
               <div id="wealth_of_evidence_bone_icon"> Burden of administration </div>
               <div id="wealth_of_evidence_list_top_tick2" class="wealth_of_evidence_list_tick_right_empty"></div>
            </div>
         </div>
         <div id="wealth_of_evidence_list_down_arrow3" class="wealth_of_evidence_hidden_content"></div>
      </div>
      <div id="wealth_of_evidence_list_holder">
         <h2 id="wealth_of_evidence_pre_sub_title" data-ag-editable="Wealth of evidence Pre Main Sub Title">Neulasta<sup>®</sup></h2>
         <h2 id="wealth_of_evidence_post_sub_title" class="wealth_of_evidence_hidden_content" data-ag-editable="Wealth of evidence Post Main Sub Title">Lipegfilgrastim<sup>8,9</sup></h2>
         <!-- List Item 1 
         <div class="wealth_of_evidence_list_item_holder">
            <div id="wealth_of_evidence_list_tick1" class="wealth_of_evidence_list_tick_left"></div>
            <div id="wealth_of_evidence_list_item1" class="wealth_of_evidence_list_items">
               <p data-ag-editable="Wealth of evidence List item 1">Works as needed by neutrophil-mediated clearance<sup>1,2,9</sup></p>
               <div class="wealth_of_evidence_list_tick_right_question wealth_of_evidence_hidden_content"></div>
               <div id="wealth_of_evidence_list_down_arrow1"></div>
            </div>
         </div>-->
         <!-- List Item 2 -->
         <div id="wealth_of_evidence_list_item2_holder" class="wealth_of_evidence_list_item_holder">
            <div id="wealth_of_evidence_list_tick2" class="wealth_of_evidence_list_tick_left"></div>
            <div id="wealth_of_evidence_list_item2" class="wealth_of_evidence_list_items">
               <p data-ag-editable="Wealth of evidence List item 2">Reduction in incidence of FN<sup>1-3,7</sup></p>
               <div class="wealth_of_evidence_list_tick_right_tick wealth_of_evidence_hidden_content"></div>
               <div id="wealth_of_evidence_list_down_arrow2"></div>
            </div>
         </div>
         <div id="wealth_of_evidence_sub_list">
            <!-- List Item 3 -->
            <div class="wealth_of_evidence_list_item_holder">
               <div id="wealth_of_evidence_list_tick3" class="wealth_of_evidence_list_tick_left"></div>
               <div id="wealth_of_evidence_list_item3" class="wealth_of_evidence_list_items">
                  <p data-ag-editable="Wealth of evidence List item 3">Reduction in hospitalization<sup>3*</sup></p>
                  <div class="wealth_of_evidence_list_tick_right_question wealth_of_evidence_hidden_content"></div>
               </div>
            </div>
            <!-- List Item 4 -->
            <div class="wealth_of_evidence_list_item_holder">
               <div id="wealth_of_evidence_list_tick4" class="wealth_of_evidence_list_tick_left"></div>
               <div id="wealth_of_evidence_list_item4" class="wealth_of_evidence_list_items">
                  <p data-ag-editable="Wealth of evidence List item 4">Helps maintain sufficient RDI<sup>4**</sup></p>
                  <div class="wealth_of_evidence_list_tick_right_question_cross wealth_of_evidence_hidden_content"></div>
               </div>
            </div>
            <!-- List Item 5 -->
            <div class="wealth_of_evidence_list_item_holder">
               <div id="wealth_of_evidence_list_tick5" class="wealth_of_evidence_list_tick_left"></div>
               <div id="wealth_of_evidence_list_item5" class="wealth_of_evidence_list_items">
                  <p data-ag-editable="Wealth of evidence List item 5">Reduction in infection-related mortality<sup>5</sup></p>
                  <div class="wealth_of_evidence_list_tick_right_question wealth_of_evidence_hidden_content"></div>
               </div>
            </div>
            <!-- List Item 6 -->
            <div class="wealth_of_evidence_list_item_holder">
               <div id="wealth_of_evidence_list_tick6" class="wealth_of_evidence_list_tick_left"></div>
               <div id="wealth_of_evidence_list_item6" class="wealth_of_evidence_list_items">
                  <p data-ag-editable="Wealth of evidence List item 6">Reduction in early mortality<sup>5</sup></p>
                  <div class="wealth_of_evidence_list_tick_right_question_double_cross wealth_of_evidence_hidden_content"></div>
               </div>
            </div>
            <!-- List Item 7 -->
            <div class="wealth_of_evidence_list_item_holder">
               <div id="wealth_of_evidence_list_tick7" class="wealth_of_evidence_list_tick_left_empty">&gt;9</div>
               <div id="wealth_of_evidence_list_item7" class="wealth_of_evidence_list_items">
                  <p data-ag-editable="Wealth of evidence List item 7">Demonstrated efficacy in various tumour types (haem/solid)<sup>6</sup></p>
                  <div id="wealth_of_evidence_list_right_tick7" class="wealth_of_evidence_list_tick_right_empty wealth_of_evidence_hidden_content">1</div>
               </div>
            </div>
         </div>
      </div>
      <div id="wealth_of_evidence_bottom_copy">
         <p data-ag-editable="Wealth of evidence Bottom Copy">Neulasta<sup>®</sup> – established by more than 10 years real-life <br/>use and a wealth of clinical evidence<sup>6,7</sup></p>
      </div>
    </div>
    <!-- Additional Popup 1 Starts -->
    <div class="lightbox_data" id="wealth_of_evidence_add_popup1">
       <div class="main_content_style">
          <div class="wealth_of_evidence_popup_holder">
            <!--  <div class="wealth_of_evidence_popup_bone_large"></div> -->
             <div class="wealth_of_evidence_popup_right_list">
                <ul data-ag-editable="Wealth of evidence Popup 1 List">
                   <li>Neulasta<sup>®</sup> vs daily filgrastim (7 RCTs) – similar incidence of bone pain in the first 4 cycles (6.6% and 7.9% for grade 3/4, respectively)<sup>1</sup></li>
                   <li>Neulasta<sup>®</sup> vs no G-CSF (5 RCTs) – grade 3/4 bone pain infrequently reported in the first cycle (3.4% and 2%, respectively)<sup>1</sup></li>
                   <li>Bone pain can be controlled in most patients with standard analgesics<sup>2</sup></li>
                   <li>Neulasta<sup>®</sup>  has more than 10 years of real-life experience<sup>1,2</sup></li>
                </ul>
             </div>
             <div class="wealth_of_evidence_popup_refs">
                <strong data-ag-editable="Wealth of evidence Popup References Title">References:</strong>
                <ol data-ag-editable="Wealth of evidenceReferences List">
                   <li>Gregory SA <em>et al</em>. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 2010; 7(7):297-308</li>
                   <li>Neulasta<sup>®</sup>, Summary Product Characteristics, July 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf</li>
                </ol>
             </div>
          </div>
       </div>
    </div>
    <!-- Additional Popup 1 Ends -->
    <!-- Additional Popup 1 Starts -->
    <div class="lightbox_data" id="wealth_of_evidence_add_popup2">
       <div class="main_content_style">
          <div class="wealth_of_evidence_popup_holder">
           <!--  <div class="wealth_of_evidence_popup_bone_large"></div> -->
             <div id="wealth_of_evidence_popup_other_list" class="wealth_of_evidence_popup_right_list">
                <ul data-ag-editable="Wealth of evidence Popup 2 List">
                   <li>Bone pain - among the treatment-emergent adverse events occurring in ≥10% of subjects in the safety population - was observed in 13.9% of subjects receiving lipegfilgrastim compared to 9.9% of subjects treated with pegfilgrastim<sup>1</sup>(P value not reported)1</li>
                   <li>“The most frequently reported adverse events considered related to the study drug were bone pain-related symptoms (14.9% for Neulasta<sup>®</sup>, 19.8% for lipegfilgrastim)”<sup>2</sup></li>

                   <li>Hypokalaemia is a common adverse event associated with lipegfilgrastim use. There is a need to monitor serum potassium level, particularly in patients with increased risk due to underlying disease or co-medications<sup>3</sup></li>
                   <li>Lipegfilgrastim treatment should be initiated and supervised by physicians experienced in oncology or haematology<sup>3</sup></li>
                </ul>
             </div>
             <div class="wealth_of_evidence_popup_refs">
                <strong data-ag-editable="Wealth of evidence Popup 1 References Title">References:</strong>
                <ol data-ag-editable="Wealth of evidence Popup 1 References List">
                   <li>Bondarenko I <i>et al.</i> Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving  oxorubicin/docetaxel chemotherapy BMC Cancer 2013, 13:386</li>
                   <li>Bondarenko IM <em>et al</em>. Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Presented at MASCC/ISOO International Symposium on Supportive Care in Cancer. New York City, June 28–30, 2012. #1010</li>
                   <li>Lonquex<sup>®</sup> Summary of Product Characteristics, September 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf</li>
                </ol>
             </div>
          </div>
       </div>
    </div>
    <!-- Additional Popup 1 Ends -->
    <!-- Reference Strong Information Starts -->
    <div class="lightbox_data" id="wealth_of_evidence_refs_strong">
       <div class="main_content_style">
          <p><strong data-ag-editable="Wealth of evidence Strong References Title">References:</strong></p>
          <div data-ag-editable="Wealth of evidence Strong References List">
             <ol>
               <!-- <li>Molineux G <em>et al</em>. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14(4):259-264</li>
                <li>Johnston E <em>et al</em>. randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18(13):2522-2528</li> -->
                <li>Cooper KL <em>et al</em>. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 23(11):404</li>
                <li>Aarts M <em>et al</em>. Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia J Clin Oncol 2013 DOI: 10.1200/JCO.2012.44.6629</li>
                <li>Almenar D <em>et al</em>. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care (Engl). 2009; 18(3):280-286</li>
                <li>Leonard R <em>et al</em>. Secondary prophylaxis with G-CSF has a major effect on delivered dose intensity: The results of the UK NCRI/Anglo Celtic SPROG trial for adjuvant chemotherapy of breast cancer. Eur J Cancer Suppl 2009; 7(2):270</li>
                <li>Kuderer N <em>et al</em>. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol. 2007;25(21):3158-3167</li>
                <li>Gregory SA <em>et al</em>. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 2010; 7(7):297-308</li>
                <li>Neulasta<sup>®</sup>, Summary Product Characteristics, July 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf</li>
             </ol>
          </div>
          <div id="refs_no_pad_copy" data-ag-editable="Wealth of evidence Strong References Bottom Copy">* due to neutropenic complications<br />** demonstrated for Neupogen<sup>®</sup> and Neulasta<sup>®</sup><br/><br/>Date of preparation: October 2013<br/> Job code: NO-IHQ-AMG-536-2013</div>
       </div>
    </div>
    <!-- Reference Strong Information Ends -->
    <!-- Reference Weak Information Starts -->
    <div class="lightbox_data" id="wealth_of_evidence_refs_weak">
       <div id="wealth_of_evidence_refs_weak_copy" class="main_content_style">
          <p><strong data-ag-editable="Wealth of evidence Weak References Title">References:</strong></p>
          <div data-ag-editable="Wealth of evidence Weak References List">
             <ol>
               <li>Cooper KL <em>et al</em>. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 23(11):404</li>
                <li>Aarts M <em>et al</em>. Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia J Clin Oncol 2013 DOI: 10.1200/JCO.2012.44.6629</li>
                <li>Almenar D <em>et al</em>. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care (Engl). 2009; 18(3):280-286</li>
                <li>Leonard R <em>et al</em>. Secondary prophylaxis with G-CSF has a major effect on delivered dose intensity: The results of the UK NCRI/Anglo Celtic SPROG trial for adjuvant chemotherapy of breast cancer. Eur J Cancer Suppl 2009; 7(2):270</li>
                <li>Kuderer N <em>et al</em>. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol. 2007;25(21):3158-3167</li>
                <li>Gregory SA <em>et al</em>. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 2010; 7(7):297-308</li>
                <li>Neulasta<sup>®</sup>, Summary Product Characteristics, July 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf</li>
                <li>Li pegfilg rastim EPAR 2013 http://vvww.ema.europa.eu/docs/en_ GB/document_li brary/EPAR_-_Public_assessment_report/human/002556/WC5001 48382.pdf</li>
                <li>Lonquex<sup>®</sup> Summary of Product Characteristics, September 2013, http://www.ema.europa.eu/docs/en_GB/document_I ibrary/EPAR_-_Product_lnformation/human/002556/WC500148380.pdf</li>
             </ol>
          </div>
          <div id="refs_no_pad_copy" data-ag-editable="Wealth of evidence Strong References Bottom Copy">? no data<br/>?† limited data<br/>?‡ conflicting data<br/>* due to neutropenic complications<br />** demonstrated for Neupogen<sup>®</sup> and Neulasta<sup>®</sup></div>
       </div>
    </div>
    <!-- Reference Weak Information Ends -->
</article>